Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Sectornieuws - Biotech en Pharma

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Sectornieuws - Biotech en Pharma

690 Posts
Pagina: «« 1 ... 30 31 32 33 34 35 »» | Laatste | Omlaag ↓
  2. forum rang 10 voda 6 december 2010 21:21
    Ceo Pfizer onverwacht opgestapt
    6 december 2010, 7:50 uur | FD.nl
    Ceo Jeffrey Kindler van farmaconcern Pfizer is onverwacht vertrokken bij het bedrijf om 'zichzelf weer op te laden'. Oudgediende Ian Read neemt het roer over.

    Kindler (55) was vierenhalf jaar in functie bij Pfizer en gaat met pensioen. In een verklaring zegt Kindler dat hij van plan is 'zichzelf weer op te laden' en dat hij meer tijd met zijn familie wil doorbrengen.

    De 57-jarige Read leidt de wereldwijde biofarmaceutische afdeling van Pfizer.

    'Ontslag'

    Analisten zeggen tegen persbureau AP dat het vertrek van Kindler als ontslag opgevat moet worden. Zij wijzen op mislukte pogingen van Kindler om nieuwe, goedverkopende medicijnen te ontwikkelen. Ook zou Kindler een gebrekkig antwoord hebben gehad op het verlopen van patenten van Pfizer, waardoor de inkomsten onder druk komen te staan.

    etc.
    www.fd.nl/artikel/20868802/ceo-pfizer...
  5. [verwijderd] 7 december 2010 12:24
    GlaxoSmithKline To Buy Nanjing MeiRui Pharmaceuticals For $70M
    Last update: 12/7/2010 3:54:16 AM

    LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), the drug giant, Tuesday announced that it has entered into an agreement to acquire Nanjing MeiRui Pharma Co., Ltd for a cash consideration of $70 million.

    MAIN FACTS:

    -Ninety per cent of the share capital of MeiRui is to be acquired from Pagoda Pharmaceuticals Limited and the remaining ten per cent from Allergon AB in a move to further expand GSK's presence in China, one of the fastest-growing and most significant of the emerging markets.

    -MeiRui is a leading Chinese pharmaceutical business with a strong portfolio of urology and allergy products, including Prostat for benign prostatic hyperplasia and Sheniting for overactive bladder syndrome. -Completion of the transaction is expected by the end of 2010, subject to regulatory approval.

    -Shares at 0850 GMT up 0.32% at 1241 pence valuing the company at GBP64.26 billion.

    -By Jana Weigand, Dow Jones Newswires; 44-20-7842-9314; jana.weigand@dowjones.com
  7. forum rang 4 aossa 7 december 2010 16:49
    Moeten we hieruit begrijpen dat de GAVI geldschieters niet opgezet zijn met de jongste stand van zaken?

    => overname van Wyeth door Pfizer (cq pneumokokken programma)

    => op til zijnde overname Crucell (cq pentavalent & hexa- programma)

    Bill & Melissa julli hebben toch een mannetje bij de Crucell board, laten jullie eens iets horen!
  8. flosz 7 december 2010 17:22
    Bij GAVI tweet men gewoon door:
    Meningitis vaccine introduced in Africa's 'meningitis belt'
    www.gavialliance.org/media_centre/sta...
    MenAfriVac: by Serum Institute of India twitter.com/GAVIAlliance
    (één op twee kinderen ter wereld: een vaccin van het Serum Institute)
    GAVI Alliance set to save four million lives by 2015 ow.ly/1ag54b
    Ook de foundation tweet als iedere dag: twitter.com/gatesfoundation

    Misschien kan de Panacea fam. Jain wel even bijspringen…
  9. forum rang 4 aossa 7 december 2010 18:04
    quote:

    flosz schreef:

    Misschien kan de Panacea fam. Jain wel even bijspringen…
    De goud- en diamanthandel draait opnieuw op volle toeren ondanks de problemen met transporter Brinkx.

    In India is het Diwali (nieuwjaarsfeest) en wordt goud en diamant gekocht voor de geliefden. De Jain's offeren dan eveneens in hun tempels (= systeem van herverdeling).

    nl.wikipedia.org/wiki/Ja%C3%AFnisme

    De grootste jaïntempel buiten India wordt te Wilrijk gebouwd. Hij zal meer dan 1000 m² groot zijn en opgetrokken worden in witte marmer. Die is vooraf in India bewerkt alvorens naar Antwerpen te worden verscheept. De totale kosten worden geraamd op 15 à 25 miljoen Euro. Dit wordt gefinancierd door de Antwerpse jaïn-gemeenschap (ongeveer 400 families). Deze is vooral actief in de handel en bewerking van diamant. De tempel zal ook een informatiecentrum over het jaïnisme bevatten.
  13. maxen 8 december 2010 00:21
    quote:

    flosz schreef:

    [...]
    5 wkn te vroeg...
    Latest news from GAVI insiders: "total chaos", no leader, and no fundraising strategy. GAVI needs urgent attention. But from whom?
    twitter.com/lancet1

    Dan kan deze er ook nog wel bij. Zelfde bron:

    Bill Gates' obsession with polio is distorting priorities in other critical BMGF areas. Global health does not depend on polio eradication.
  14. forum rang 10 voda 8 december 2010 20:19
    Farmacieconcern Bayer verhoogt uitgaven R&D
    8 december 2010, 15:10 uur | FD.nl
    Door: Henk Engelenburg

    Het Duitse farma- en chemieconcern Bayer verhoogt de uitgaven aan onderzoek en ontwikkeling dit jaar met € 350 mln, ofwel 13%, tot € 3,1 mrd.

    ....

    Pijplijn

    Terwijl de meeste grote farmabedrijven in de wereld worstelen met het vinden van nieuwe medicijnen, rept Bayer gisteren van een pijplijn van meer dan vijftig kandidaat-medicijnen die al op mensen worden getest, de zogeheten derde en laatste fase van ontwikkeling.

    Bayer verwacht dat het met xarelto, een nieuw middel om trombose te voorkomen, dat het samen met Johnson&Johnson is ontwikkeld, een omzet op jaarbasis zal krijgen van € 2 mrd. Dekkers: 'Vergeet echter niet dat de ontwikkeling van het middel vele jaren heeft geduurd, voor € 2 mrd aan kosten. En om xarelto in 200 landen op de markt te brengen, kost eveneens ongelooflijk veel geld.'

    etc.

    www.fd.nl/artikel/20891677/farmacieco...
  16. forum rang 10 voda 9 december 2010 15:57
    Bayer investeert miljard in China
    9 december 2010, 8:40 | ANP
    SHANGHAI (AFN) - Het Duitse chemie- en farmacieconcern Bayer investeert de komende vijf jaar nog eens 1 miljard euro in China. Dit heeft Bayer donderdag bekendgemaakt.

    Het concern steekt het geld in uitbreiding van zijn productiefaciliteiten in Shanghai. De nieuwe investering komt bovenop de 2,1 miljard euro die al eerder was aangekondigd. Ook dat geld wordt in de vestiging in Shanghai gestoken.

    ,,De uitbreiding van onze capaciteiten in China is een belangrijke stap om onze aanwezigheid in de groeilanden duidelijk te vergroten'', aldus topman Marijn Dekker van Bayer. ,,De sterke economische groei in China en de hele regio biedt ons uitstekende kansen en wij willen daar het beste van maken.''

  17. flosz 10 december 2010
    quote:

    flosz schreef:

    5 wkn te vroeg...
    Latest news from GAVI insiders: "total chaos", no leader, and no fundraising strategy. GAVI needs urgent attention. But from whom?
    twitter.com/lancet1

    Volgens Rosenthal & Knapen….
    Antwoorden op Kamervragen ter voorbereiding WGO
    Vragen gesteld door Vaste Kamercommissie
    Kamerstuknummer: 32500-V-00

    Vraag 228:
    Waarom wordt er op GAVI niet bezuinigd? Is dit in het belang van het Nederlandse bedrijfsleven?
    Antwoord:
    GAVI, de Global Alliance for Vaccines and Immunisation , is een effectief en innovatief publiekprivaat partnerschap. GAVI is een betrouwbare partner met concrete resultaten.
    Sinds de oprichting in 2000 meer dan 257 miljoen extra kinderen gevaccineerd. Hierdoor zijn 5,4 miljoen gevallen van kindersterfte voorkomen.
    Tijdens de G20 top in juni jongstleden in Canada heeft toenmalig Minister President Balkenende namens Nederland een nieuwe bijdrage aan GAVI toegezegd.
    Het Nederlandse bedrijf Crucell is een van de leveranciers van vaccins.
    tinyurl.com/26mwsrm
  18. [verwijderd] 10 december 2010 11:25
    WikiLeaks Documents: Pfizer Sought Evidence Of Nigerian Corruption
    Last update: 12/10/2010 4:38:26 AM

    LONDON (Dow Jones)--Drug maker Pfizer Inc. (PFE) hired investigators to unearth evidence of corruption against the Nigerian attorney general in order to persuade him to drop legal action over a controversial drug trial involving children with meningitis, The Guardian reports Friday, citing a leaked U.S. embassy cable made public by WikiLeaks.

    The report says Pfizer was sued by the Nigerian state and federal authorities, who claimed that children were harmed by a new antibiotic, Trovan, during the trial, which took place in the middle of a meningitis epidemic of unprecedented scale in Kano, northern Nigeria, in 1996.

    Last year, the company came to a tentative settlement with the Kano state government, which was to cost it $75 million, the report says. However it cites the cable as suggesting that the U.S. drug giant didn't want to pay out to settle the two cases--one civil and one criminal--brought by the Nigerian federal government.

    The report says the cable details a meeting between Pfizer's country manager, Enrico Liggeri, and U.S. officials at the Abuja embassy on 9 April 2009, saying that--according to Liggeri--Pfizer had hired investigators to uncover corruption links to federal attorney general Michael Aondoakaa to expose him and put pressure on him to drop the federal cases. A Pfizer spokesperson wasn't immediately available for comment Friday.

    Newspaper Website: www.guardian.co.uk -London Bureau, Dow Jones Newswires; +44 (0)20 7842 9320 (END)

    Dow Jones Newswires

    December 10, 2010 04:38 ET (09:38 GMT)
  19. [verwijderd] 10 december 2010 19:06
    Beckman Coulter Likely To Attract Variety Of Suitors
    Last update: 12/10/2010 12:17:35 PM
    By Jennifer Cummings
    Of DOW JONES NEWSWIRES
    NEW YORK (Dow Jones)--Beckman Coulter Inc. (BEC) is likely to appeal to a variety of suitors in its attempt to sell itself, with the medical-testing company offering a buyer quick access to the growing global diagnostics industry. Moreover, with shares at a more than two-year high Friday, it looks like the market is betting the company will succeed in finding a buyer, despite Beckman's recent struggles with a diagnostic-test recall that hurt its image on Wall Street.

    Shares of Beckman were recently up 28% to $72.79. They earlier traded as high as $74.85; the stock hasn't closed above that level since September 2008. The gains came after The Wall Street Journal reported late Thursday that Beckman, which makes diagnostic instruments used in clinical testing, has put itself up for sale and could fetch more than $5 billion. The paper, citing people familiar with the matter, said several large private-equity firms and rival companies have expressed interest in Beckman, which had a market value of just under $4 billion Thursday.

    Rivals like Abbott Laboratories (ABT) or Johnson & Johnson (JNJ)[s][/s] were named by analysts as potential suitors since a Beckman acquisition could allow them to enhance their product positioning. However, with the diagnostics sector already fairly consolidated, a sale of Beckman to a peer would likely come under heavy regulatory scrutiny, according to GARP Research & Securities analyst Alastair Mackay.

    Beckman may also appeal to new entrants who want access to the diagnostics industry, which has been growing as medical tests have evolved and become more informative. One new entrant seen as a possible suitor is General Electric Co. (GE), which unsuccessfully tried to acquire certain diagnostics businesses of Abbott for $8 billion in 2007. GE has a medical-imaging division, which markets equipment like CT and MRI scanners, that analysts say could be a good fit with Beckman's diagnostics testing business.

    Abbott and GE couldn't immediately be reached for comment, while a Johnson & Johnson representative declined to comment. It's possible Beckman will just be taken private. It's likely to appeal to private-equity firms that they can install one of their own to chart Beckman's direction. The company is looking for a new chief executive after Scott Garrett abruptly resigned in September.

    "A private-equity option would likely serve as a viable leadership answer to turn around the company," Canaccord Genuity analyst Jeff Frelick said. Analysts also pointed to Beckman's strong cash flow as another lure for private equity. Meanwhile, Macquarie was cautious, noting that there are still many unknowns with Beckman's business that could dissuade private-equity investors from paying too much. Talk of a sale comes in a tumultuous year for the company.

    Due to faulty results, Beckman earlier this year recalled a test for measuring a protein that signals heart problems. Beckman also came under fire from the Food and Drug Administration, which believes the company marketed that test without needed agency clearance.

    -By Jennifer Cummings, Dow Jones Newswires; 212-416-2474; jennifer.cummings@dowjones.com (Anupreeta Das, Gina Chon and Jon Kamp contributed to this article.) (END)

    Dow Jones Newswires

    December 10, 2010 12:17 ET (17:17 GMT)
  20. [verwijderd] 15 december 2010 15:27
    Adimab Announces New Discovery Programs with Eli Lilly, Genentech and Human Genome Sciences

    Last update: 12/15/2010 9:05:01 AM

    LEBANON, N.H., Dec 15, 2010 (BUSINESS WIRE) -- Adimab, Inc., a technology leader in the discovery of fully human antibodies, today announced the initiation of three new independent research collaborations with Eli Lilly, Genentech, and Human Genome Sciences. Over the past 18 months Adimab has established collaborations with several leading Pharmaceutical companies including: Merck, Roche, Novartis, Pfizer, and now Eli Lilly, Genentech, and Human Genome Sciences.

    "As more companies develop therapeutic leads against the same validated disease targets, leading Pharma companies are actively seeking out technologies that give them a meaningful advantage and Adimab's deal flow speaks for itself," said Tillman Gerngross, Adimab's CEO and co-founder.

    "In this highly competitive environment, having access to the best technology becomes essential, not optional. Our ability to provide high quality leads in a matter of months is driving the demand for our technology."

    In addition to the three new collaborations, Adimab announced the achievement of a technical milestone in its ongoing collaboration with Novartis, which was initiated in June of 2010. Adimab also announced that Merck has exercised its option to start an additional project around a 2nd target.

    "Adimab's platform is unique in comparison to any other antibody discovery technology. By incorporating target biology into the selection process we are able to generate very high quality leads in a short timeframe," said Guy Van Meter, Adimab's Senior Director of Business Development. "The most sophisticated buyers in the industry understand the impact Adimab could have on their pipelines.

    Since launching the platform in June of 2009, we have closed a total of 15 funded discovery programs, including 10 new programs in 2010." About Adimab's New Discovery Deals Adimab and Lilly have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Lilly.

    For each target, the agreement grants Lilly the right to research antibodies generated from the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive various upfront fees including research fees and technical milestones. In addition, for each target, Lilly will have the sole option to exclusively license antibodies from the collaboration, and if Lilly were to exercise the option for a particular target, then Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales for such target.

    Adimab and Genentech, Inc., a member of the Roche Group (six:RO)(six:ROG)(otcqx:RHHBY) have initiated a research program whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against two targets selected by Genentech. Under the terms of the agreement, Genentech has rights to commercialize antibodies generated from the collaboration.

    Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones and royalties on therapeutic and diagnostic product sales. Adimab and Human Genome Sciences, of Rockville MD, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against one target selected by Human Genome Sciences.

    The agreement gives Human Genome Sciences the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales. About Adimab Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs.

    Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressibility. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

    For more information, visit .

    SOURCE: Adimab Adimab, Inc. Guy Van Meter, 603-727-7107 x175 Senior Director, Head of Business Development or MacDougall Biomedical Communications Chris Erdman, 781-235-3060

    Copyright Business Wire 2010
690 Posts
Pagina: «« 1 ... 30 31 32 33 34 35 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 909,96 -0,38%
EUR/USD 1,0872 -0,11%
FTSE 100 8.415,10 -0,36%
Germany40^ 18.828,50 -0,22%
Gold spot 2.386,27 -0,01%
NY-Nasdaq Composite 16.742,39 +1,40%

Stijgers

Vastned
+3,32%
JUST E...
+2,28%
ASMI
+1,94%
BESI
+1,81%
INPOST
+1,54%

Dalers

SIGNIF...
-4,57%
OCI
-2,26%
IMCD
-2,17%
Avantium
-2,14%
SHELL PLC
-2,08%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!